Founder and CEO of Brooks Bell Inc.
Managing director, the Foundry Group
Founder and Chairman, Sycamore Networks
Co-Founder and CEO, DNAnexus
Head of global research and development at Life Technologies
Executive Partner, Sofinnova Ventures
Nobel Laureate, Professor of Biology, Caltech
Professor, Michigan State University
Syntimmune, a biotech startup formed by the veteran founders of the hemophilia drug developer Syntonix, has been acquired by Alexion Pharmaceuticals for $400 million in cash up front.
Syntimmune is right in Alexion’s (NASDAQ: ALXN) wheelhouse. The Boston-based firm is... Read more »
These days biotechs are raising cash and going public at a record pace. But before the Wall Street buzz and the big raises, they all started somewhere—with an idea, a pitch, and perhaps a little luck.
Xconomy dives into these... Read more »
San Antonio—VelocityTX has selected eight startups from South America to join its Global Accelerator Program, which offers three months of training and information on building a business in the U.S.
The program requires the companies to open a satellite office... Read more »
Those of us keeping tabs on the mobility industry have heard a lot about the development of sensors and other computer vision technologies to help autonomous vehicles “see” and interpret the landscape around them. WaveSense, a startup spun out of... Read more »
Gemphire Therapeutics is laying off five, including two executives, as the company grapples with clinical trial setbacks for its lead drug candidate.
Chief Financial Officer Jeffrey Mathieson and Chief Medical Officer Lee Golden have left Livonia, MI-based Gemphire (NASDAQ: GEMP),... Read more »
Morphic Therapeutic, a startup from Harvard scientist-entrepreneur Tim Springer, has reloaded with an $80 million Series B round that should get the company to its first human tests.
The round includes a number of crossover investors (including Invus and EcoR1; Novo... Read more »
Alexion Pharmaceuticals’ flagship drug has made a strong case it can treat yet another rare disease, and the company is now mapping out plans to file for approval in the U.S. and other regions.
The Boston company released preliminary Phase 3... Read more »
With fall officially here, it’s time to ask some big questions about the coming year—and decade.
What will be the most transformative technology areas for society and business? What should students and innovators be doing to prepare for five to 10... Read more »
Many large drug companies go to extraordinary lengths to fend off generic competition and extend the life of their patents, but Gilead today announced a highly unusual move in the opposite direction. In January 2019, the company will start selling “authorized”... Read more »
There was more news this morning in the advancement of precision cancer drugs, which target a tumor’s genetic signature. Roche plans to file for approval of entrectinib, a drug the Swiss firm acquired when it bought San Diego, CA-based Ignyta for... Read more »
Can fish oil help prevent, or reduce the risk of heart disease? Several studies have failed to show that it can. But Amarin this morning is releasing data from a massive study showing that its prescription-grade fish oil pill, Vascepa, has... Read more »
Marketo almost didn’t get off the ground.
It was 2006, and Jon Miller and his Marketo co-founders were struggling to raise money from investors for their marketing technology startup. Their pitch was to use software to help businesses automate much of... Read more »
Equillium, a biotech startup developing treatments for immune system disorders—including an immune response that affects some transplant recipients—is preparing for an IPO to finance tests of its lead drug.
The company set a preliminary IPO target of $86 million, according to... Read more »
TitleTownTech, a soon-to-be-launched joint venture between the NFL’s Green Bay Packers and tech giant Microsoft, has hit the brakes on a startup accelerator the two organizations had previously said they planned to run together.
Craig Dickman, whom the Packers named... Read more »
Sigstr, the Indianapolis-based marketing tech startup, announced this week that it has raised $4 million in new venture funding. The round was led by Edison Partners, with participation from past investors, including Hyde Park Venture Partners, HubSpot Ventures... Read more »
Cancer drug developer Y-mAbs Therapeutics is the latest biotech company to go public, raising $96 million in its IPO.
New York-based Y-mAbs priced its offering of 6 million shares at $16 each, which was the high end of its projected range.... Read more »
Tech giant Adobe announced Thursday it is buying marketing-software firm Marketo for $4.75 billion. The move may have a ripple effect on the realm of enterprise sales and marketing.
Marketo, based in San Mateo, CA, was founded in 2006 and built... Read more »
Sarepta Therapeutics won one of the most controversial drug approvals in recent memory, when the FDA in September 2016 approved the Duchenne muscular dystrophy drug eteplirsen (Exondys 51) off a slim set of data. The Cambridge, MA, company isn’t having the... Read more »
Biotech company uBiome started as a “citizen science” project that collected and studied microbiome samples in order to learn how the trillions of bacteria living in and on people’s bodies affect human health.
Six years and 250,000 samples later, uBiome is... Read more »
San Antonio — Life science groups, city officials, and research institutes in San Antonio are organizing an effort to commercialize more scientific developments coming out of the city’s military organizations.
The goal of the project is to develop an alliance between... Read more »
The U.S. Senate had a rare moment of agreement, overwhelmingly passing a package of opioid-related bills. Up the East Coast, life-science players in Rhode Island are working to bring different local factions together and boost the state’s economy. Across the country,... Read more »
Convoy, an online marketplace that connects shippers with freight truck fleets and independent drivers, announced today it raised $185 million in a Series C fundraising round led by CapitalG, the growth equity investment fund of Alphabet, Google’s parent company.
With... Read more »
CEO of Project Foundry
Founder and Managing Director of DEV
Professor of Systems Biology, Columbia University
Managing Director, D.E. Shaw and Co., L.P.
CEO, FullContact
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
